The effects of hormone replacement therapy and raloxifene
on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.
A meta-analysis study has demonstrated the efficacy of anti-resorptive agents: raloxifene
and etidronate have been shown to reduce the incidence of vertebral fractures, and alendronate and risedronate have been shown to reduce the incidence of both vertebral and hip fractures.
company cannot predict whether generic raloxifene
will be marketed prior to the
and tamoxifen are broadly similar in reducing breast cancer risk, raloxifene
also appears to lower the odds of developing endometrial cancer, researchers report in the September 1st issue of the Journal of Clinical Oncology.
Scientists stumbled on the discovery while investigating whether the drug, raloxifene
, protects against heart disease.
Preliminary results of a 2006 study on postmenopausal women found that the osteoporosis drug raloxifene
(Evista) was as effective as tamoxifen at lowering breast cancer risk in high risk women, with slightly fewer side effects.
Despite concerns over cardiovascular side effects, an FDA panel recommended the osteoporosis drug raloxifene
(drug name Evista) for prevention of breast cancer in certain groups of women at high risk for the disease.
is a selective estrogen receptor modulator, specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial and breast tissue.
Materials and Methods: Investigators identified a continuously benefit-eligible cohort of women from a large, geographically diverse, national managed care plan who were newly diagnosed and treated for osteoporosis with alendronate, risedronate, or raloxifene
Scientists designed the study to compare oral doses of the osteoporosis drug raloxifene
(Evista) with tamoxifen (Nolvadex) taken for 5 years.
US scientists studied the effects of raloxifene
and tamoxifen on more than 19,000 post-menopausal women.
American scientists studied the effects of raloxifene
(Evista) and tamoxifen on more than 19,000 post-menopausal women.